165 related articles for article (PubMed ID: 30827244)
1. Acid Ceramidase: A Novel Therapeutic Target in Cancer.
Vijayan Y; Lankadasari MB; Harikumar KB
Curr Top Med Chem; 2019; 19(17):1512-1520. PubMed ID: 30827244
[TBL] [Abstract][Full Text] [Related]
2. Acid ceramidase, an emerging target for anti-cancer and anti-angiogenesis.
Cho SM; Kwon HJ
Arch Pharm Res; 2019 Mar; 42(3):232-243. PubMed ID: 30661200
[TBL] [Abstract][Full Text] [Related]
3. Acid ceramidase is upregulated in AML and represents a novel therapeutic target.
Tan SF; Liu X; Fox TE; Barth BM; Sharma A; Turner SD; Awwad A; Dewey A; Doi K; Spitzer B; Shah MV; Morad SA; Desai D; Amin S; Zhu J; Liao J; Yun J; Kester M; Claxton DF; Wang HG; Cabot MC; Schuchman EH; Levine RL; Feith DJ; Loughran TP
Oncotarget; 2016 Dec; 7(50):83208-83222. PubMed ID: 27825124
[TBL] [Abstract][Full Text] [Related]
4. Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.
Morad SA; Levin JC; Tan SF; Fox TE; Feith DJ; Cabot MC
Biochim Biophys Acta; 2013 Dec; 1831(12):1657-64. PubMed ID: 23939396
[TBL] [Abstract][Full Text] [Related]
5. Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK-mediated signalling.
Klobučar M; Grbčić P; Pavelić SK; Jonjić N; Visentin S; Sedić M
Biochem Biophys Res Commun; 2018 Sep; 503(2):843-848. PubMed ID: 29920241
[TBL] [Abstract][Full Text] [Related]
6. N-Metallocenoylsphingosines as targeted ceramidase inhibitors: Syntheses and antitumoral effects.
Rothemund M; Bär A; Klatt F; Weidler S; Köhler L; Unverzagt C; Kuhn CD; Schobert R
Bioorg Chem; 2020 Apr; 97():103703. PubMed ID: 32143017
[TBL] [Abstract][Full Text] [Related]
7. The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.
Tan SF; Pearson JM; Feith DJ; Loughran TP
Expert Opin Ther Targets; 2017 Jun; 21(6):583-590. PubMed ID: 28434262
[TBL] [Abstract][Full Text] [Related]
8. Sphingolipids and acid ceramidase as therapeutic targets in cancer therapy.
Govindarajah N; Clifford R; Bowden D; Sutton PA; Parsons JL; Vimalachandran D
Crit Rev Oncol Hematol; 2019 Jun; 138():104-111. PubMed ID: 31092365
[TBL] [Abstract][Full Text] [Related]
9. Acid ceramidase as a chemotherapeutic target to overcome resistance to the antitumoral effect of choline kinase α inhibition.
Ramírez de Molina A; de la Cueva A; Machado-Pinilla R; Rodriguez-Fanjul V; Gomez del Pulgar T; Cebrian A; Perona R; Lacal JC
Curr Cancer Drug Targets; 2012 Jul; 12(6):617-24. PubMed ID: 22515519
[TBL] [Abstract][Full Text] [Related]
10. Targeting ceramide metabolic pathway induces apoptosis in human breast cancer cell lines.
Vethakanraj HS; Babu TA; Sudarsanan GB; Duraisamy PK; Ashok Kumar S
Biochem Biophys Res Commun; 2015 Aug; 464(3):833-9. PubMed ID: 26188095
[TBL] [Abstract][Full Text] [Related]
11. Novel agents targeting bioactive sphingolipids for the treatment of cancer.
Adan-Gokbulut A; Kartal-Yandim M; Iskender G; Baran Y
Curr Med Chem; 2013; 20(1):108-22. PubMed ID: 23244584
[TBL] [Abstract][Full Text] [Related]
12. Acid ceramidase as a therapeutic target in metastatic prostate cancer.
Camacho L; Meca-Cortés O; Abad JL; García S; Rubio N; Díaz A; Celià-Terrassa T; Cingolani F; Bermudo R; Fernández PL; Blanco J; Delgado A; Casas J; Fabriàs G; Thomson TM
J Lipid Res; 2013 May; 54(5):1207-20. PubMed ID: 23423838
[TBL] [Abstract][Full Text] [Related]
13. Genetic and pharmacological inhibition of acid ceramidase prevents asymmetric cell division by neosis.
White-Gilbertson S; Lu P; Norris JS; Voelkel-Johnson C
J Lipid Res; 2019 Jul; 60(7):1225-1235. PubMed ID: 30988134
[TBL] [Abstract][Full Text] [Related]
14. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy.
Liu X; Cheng JC; Turner LS; Elojeimy S; Beckham TH; Bielawska A; Keane TE; Hannun YA; Norris JS
Expert Opin Ther Targets; 2009 Dec; 13(12):1449-58. PubMed ID: 19874262
[TBL] [Abstract][Full Text] [Related]
15. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
Roh JL; Park JY; Kim EH; Jang HJ
Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
[TBL] [Abstract][Full Text] [Related]
16. Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites.
Bai A; Bielawska A; Rahmaniyan M; Kraveka JM; Bielawski J; Hannun YA
Bioorg Med Chem; 2018 Dec; 26(23-24):6067-6075. PubMed ID: 30448190
[TBL] [Abstract][Full Text] [Related]
17. Acid ceramidase inhibition: a novel target for cancer therapy.
Liu X; Elojeimy S; Turner LS; Mahdy AE; Zeidan YH; Bielawska A; Bielawski J; Dong JY; El-Zawahry AM; Guo GW; Hannun YA; Holman DH; Rubinchik S; Szulc Z; Keane TE; Tavassoli M; Norris JS
Front Biosci; 2008 Jan; 13():2293-8. PubMed ID: 17981711
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.
Morad SA; Cabot MC
Biochim Biophys Acta; 2015 Sep; 1851(9):1134-45. PubMed ID: 25964209
[TBL] [Abstract][Full Text] [Related]
19. Ceramidases, roles in sphingolipid metabolism and in health and disease.
Coant N; Sakamoto W; Mao C; Hannun YA
Adv Biol Regul; 2017 Jan; 63():122-131. PubMed ID: 27771292
[TBL] [Abstract][Full Text] [Related]
20. Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy.
Huwiler A; Pfeilschifter J
Curr Pharm Des; 2006; 12(35):4625-35. PubMed ID: 17168766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
